News at Geistlich Pharma AG

2021 · 2020 · 2019 · 2018 · 2017 · 2016 · 2015 · 2014 · 2013 ·
  • As of today, Geistlich Biomaterials' "The New Daily Practice" website is live!

  • The new Geistlich podcast is here. It accompanies you on the journey to our in-house research & development. Immerse yourself in the world of Geistlich, the regeneration specialist, with Dr. Mark Spilker, Geistlich Pharma’s Chief Scientific Officer, and Dr. Marco Zeltner, a specialist in reconstructive dentistry.

  • After a global slump in sales due to the coronavirus pandemic, Geistlich Pharma rebounded quickly across the board from the middle of the year. The Asia-Pacific region in particular is back on track and showing important momentum for growth. The pandemic and the high value of the Swiss franc continue to present challenges.

  • Out of the 6,000 people who participated in “Geistlich + YOU2”, 1,050 actively took part in the virtual hands-on workshop given by Prof. Dr. Ronald E. Jung. It is probably the largest workshop dental training has ever seen. Enthusiastic workshop participants shared their impressions on "Instagram". The opening question was: “How can I improve my implant therapy and pick up knowledge for my next treatment”?

  • Geistlich Pharma has been granted Breakthrough Device Designation for Chondro-Gide® by the US Food and Drug Administration (FDA). Chondro-Gide® is a collagen membrane that is used in a one-step cartilage repair technique.

  • Over 6000 specialists in dentistry have benefited from the knowledge of top-class, international experts. The online congress focused on offering valuable insight into developments in regenerative dentistry. In addition, 1050 participants actively took part in the probably largest virtual hands-on workshop in dentistry.

  • In January 2021, Lehman (Lei Min) Gu has taken up the position as General Manager at Geistlich Pharma China. He follows Qiu Wang, who has been in charge of Geistlich China since its inception in early 2007.

  • People from 100 nations will be attending this congress and you can be right at the heart of it too. Taking part in “Geistlich + YOU2” will allow you to benefit from a transfer of knowledge from the best in the sector, take part in discussions and work alongside them.

  • In January 2021, Ralf P. Halbach has taken up the position as designated CEO at Geistlich Pharma. As of July 1, 2021, he will officially take over from Paul Note, who has reached retirement age. A smooth handover will take place until then.

  • After a long run of 3,988 kilometers, Geistlich Pharma’s annual donation found its destiny – Geistlich handed it over in São Paulo to the non-profit organization (NGO) Turma do Bem.

Dr. Mirjam Kessler
Director Corporate Communications